Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure
Shionogi Co., Ltd. (TYO: 4507) announced that its U.S. subsidiary, Shionogi Inc., has been awarded...
Drug
Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China’s National Medical Products Administration...
Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...
Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig,...
Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure
Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast...
GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio
GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...
Aidea Pharma’s Novel HIV-1 Capsid Inhibitor ACC085 Cleared for PrEP Trial in China, Targeting Long-Acting Prevention
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) has secured clinical trial approval from China’s National...
Gan & Lee Pharmaceuticals Launches China’s First AR-Targeting PROTAC into Phase I Trial for Advanced Prostate Cancer
Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National...
Amgen’s Subcutaneous Tepezza via On-Body Injector Meets Phase III Endpoint in Thyroid Eye Disease with 77% Proptosis Response
Amgen Inc. (NASDAQ: AMGN) announced positive top-line results from a Phase III clinical trial evaluating...
Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent
China’s National Medical Products Administration (NMPA) has granted marketing approval for higenamine, a Category 1...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) announced it has received approval from China’s...
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...
Merck’s KEYTRUDA Receives EU Approval for Platinum-Resistant Ovarian Cancer in Combination Regimen
Merck & Co., Inc. (MSD, NYSE: MRK) announced that the European Commission has granted marketing...
Merck Launches Pivotal Phase 2b/3 Trial for MK-8748 Bispecific Antibody in Wet AMD Treatment
Merck & Co., Inc. (MSD, NYSE: MRK) announced the initiation of a pivotal Phase 2b/3...
Bio-Thera Solutions Gains NMPA Clearance for Phase I/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors
Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved...
AstraZeneca’s Imfinzi-Imjudo Combo with Lenvatinib and TACE Shows Significant PFS Benefit in Early-Stage Liver Cancer, EMERALD-3 Trial Reveals
AstraZeneca plc (NYSE: AZN) announced positive top-line results from the EMERALD-3 Phase III clinical trial,...
RemeGen Secures NMPA Approval for Phase I/IIa Trial of Bispecific ADC RC288 Targeting PSMA and B7H3 in Solid Tumors
RemeGen Ltd (HKG: 9995) announced it has received approval from China’s National Medical Products Administration...
Fosun Pharma Secures NMPA Approval for Phase I Trial of HLX319, Biosimilar to Roche’s Phesgo for HER2-Positive Breast Cancer
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received approval...
NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide...
Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received approval from China’s National...